QbD-driven development and evaluation of nanostructured lipid carriers (NLCs) of Olmesartan medoxomil employing multivariate statistical techniques

References

• Mustata G, Dinh SM. Approaches to oral drug delivery for challenging molecules. Crit Rev Ther Drug Carrier Syst. 2006;23:111–135.
   PubMed Web of Science ®Google Scholar
• Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 2014;13:655–672.
   PubMed Web of Science ®Google Scholar
• Beg S, Swain S, Rizwan M, et al. Bioavailability enhancement strategies: basics, formulation approaches and regulatory considerations. Curr Drug Deliv. 2011;8:691–702.
   PubMed Web of Science ®Google Scholar
• Stegemann S, Leveiller F, Franchi D, et al. When poor solubility becomes an issue: from early stage to proof of concept. Eur J Pharm Sci. 2007;31:249–261.
   PubMed Web of Science ®Google Scholar
• Rahman MA, Harwansh R, Mirza MA, et al. Oral lipid based drug delivery system (LBDDS): formulation, characterization and application: a review. Curr Drug Deliv. 2011;8:330–345.
   PubMed Web of Science ®Google Scholar
• Kalepu S, Manthina M, Padavala V. Oral lipid-based drug delivery systems: an overview. Acta Pharm Sin B. 2013;3:361–372.
   Web of Science ®Google Scholar
• Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54(1):S131–S155.
   Web of Science ®Google Scholar
• Pardeike J, Hommoss A, Muller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366:170–184.
   PubMed Web of Science ®Google Scholar
• Norwood D, Branch E III, Smith B, et al. Olmesartan medoxomil for hypertension: a clinical review. Drug Forecast. 2002;27:611–618.
   Google Scholar
• Warner GT, Jarvis B. Olmesartan medoxomil. Drugs. 2002;62:1345–1353.
   PubMed Web of Science ®Google Scholar
• Laeis P, Puchler K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens Suppl. 2001;19:S21–S32.
   PubMedGoogle Scholar
• Singh B, Beg S, Raza K. Developing optimized drug products employing design of experiments. Chem Industry Digest. 2013;23:70–76.
   Google Scholar
• Singh B, Beg S. Quality by design in product development life cycle. Chron Pharmabiz. 2013;22:72–79.
   Google Scholar
• Fahmy R, Kona R, Dandu R, et al. Quality by design I: application of failure mode effect analysis (FMEA) and Plackett-Burman design of experiments in the identification of “main factors” in the formulation and process design space for roller-compacted ciprofloxacin hydrochloride immediate-release tablets. AAPS PharmSciTech. 2012;13:1243–1254.
   PubMed Web of Science ®Google Scholar
• Zhao YQ, Wang LP, Ma C, et al. Preparation and characterization of tetrandrine-phospholipid complex loaded lipid nanocapsules as potential oral carriers. Int J Nanomed. 2013;8:4169–4181.
   PubMed Web of Science ®Google Scholar
• Beg S, Sharma G, Katare OP, et al. Development and validation of a stability-indicating liquid chromatographic method for estimating olmesartan medoxomil using quality by design. J Chromatogr Sci. 2015;53:1048–1059.
   PubMed Web of Science ®Google Scholar
• Singh B, Singh S. A comprehensive computer program for study of drug release kinetics from compressed matrices. Indian J Pharm Sci. 1998;60:313–316.
   Google Scholar
• Singh B, Kaur J, Singh S. Correction of raw dissolution data for loss of drug during sampling. Indian J Pharm Sci. 1997;59:196–199.
   Google Scholar
• Lambert WJ. Considerations in developing a target product profile for parenteral pharmaceutical products. AAPS PharmSciTech. 2010;11:1476–1481.
   PubMed Web of Science ®Google Scholar
• Ferreira AP, Tobyn M. Multivariate analysis in the pharmaceutical industry: enabling process understanding and improvement in the PAT and QbD era. Pharm. 2014;20:513–527.
   Google Scholar
• McKay B, Hoogenraad M, Damen EW, et al. Advances in multivariate analysis in pharmaceutical process development. Curr Opin Drug Discov Devel. 2003;6:966–977.
   PubMedGoogle Scholar
• Ke Z, Hou X, Jia XB. Design and optimization of self-nanoemulsifying drug delivery systems for improved bioavailability of cyclovirobuxine D. Drug Des Dev Ther. 2016;10:2049–2060.
   PubMed Web of Science ®Google Scholar
• Fang G, Tang B, Chao Y, et al. Improved oral bioavailability of docetaxel by nanostructured lipid carriers: in vitro characteristics, in vivo evaluation and intestinal transport studies. RSC Adv. 2015;5:96437–96447.
   Web of Science ®Google Scholar
• Dhawan S, Kapil R, Singh B. Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery. J Pharm Pharmacol. 2010;63:342–351.
   Web of Science ®Google Scholar
• Kasongo KW, Pardeike J, Muller RH, et al. Selection and characterization of suitable lipid excipients for use in the manufacture of didanosine-loaded solid lipid nanoparticles and nanostructured lipid carriers. J Pharm Sci. 2011;100:5185–5196.
   PubMed Web of Science ®Google Scholar
• Neves AR, Lucio M, Martins S, et al. Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. Int J Nanomedicine. 2013;8:177–187.
   PubMed Web of Science ®Google Scholar
• Pezeshki A, Ghanbarzadeh B, Mohammadi M, et al. Encapsulation of vitamin A palmitate in nanostructured lipid carrier (NLC)-effect of surfactant concentration on the formulation properties. Adv Pharm Bull. 2014;4(2):563–568.
   Google Scholar
• Dudhipala N, Veerabrahma K. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Deliv. 2016;23:395–404.
   PubMed Web of Science ®Google Scholar
• Qin Y, Xiongwei H, Yuhua M, et al. Lipids-based nanostructured lipid carriers (NLCs) for improved oral bioavailability of sirolimus. Drug Deliv. 2016;23:1469–1475.
   PubMed Web of Science ®Google Scholar
• Zhuang CY, Li N, Wang M, et al. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm. 2010;394:179–185.
   PubMed Web of Science ®Google Scholar
• Shah NV, Seth AK, Balaraman R, et al. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: design and in vivo study. J Adv Res. 2016;7:423–434.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yuan L, Zhou L, et al. Effect of cell-penetrating peptide-coated nanostructured lipid carriers on the oral absorption of tripterine. Int J Nanomed. 2012;7:4581–4591.
   PubMed Web of Science ®Google Scholar
• Raza K, Singh B, Lohan S, et al. Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity. Int J Pharm. 2013;456:65–72.
   PubMed Web of Science ®Google Scholar
• Souto EB, Mehnert W, Muller RH. Polymorphic behavior of Compritol888 ATO as bulk lipid and as SLN and NLC. J Microencapsul. 2006;23:417–433.
   PubMed Web of Science ®Google Scholar
• Subedi RK, Kang KW, Choi HK. Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. Eur J Pharm Sci. 2009;37:508–513.
   PubMed Web of Science ®Google Scholar
• Hu L, Xing Q, Meng J, et al. Preparation and enhanced oral bioavailability of cryptotanshinone-loaded solid lipid nanoparticles. AAPS PharmSciTech. 2010;11:582–587.
   PubMed Web of Science ®Google Scholar
• Kaur IP, Bhandari R, Bhandari S, et al. Potential of solid lipid nanoparticles in brain targeting. J Control Release. 2008;127:97–109.
   PubMed Web of Science ®Google Scholar